News >> CordenPharma Boulder Receives Successful FDA Inspection

Apr 04, 2018

CordenPharma is pleased to announce that in March 2018 our CordenPharma Boulder (CO, USA) manufacturing facility completed a general Inspection conducted by the US FDA. All Quality Systems were evaluated. The facility received a successful response with no FDA 483 observations reported. 
Brian McCudden, Managing Director of CordenPharma Boulder comments, “We are pleased with the outcome of the FDA Inspection in March 2018, as it reflects our willingness to comply with the highest level of cGMP regulatory compliance and represents an important milestone for our CordenPharma Boulder facility, following its acquisition from Pfizer in November of 2017.”